Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzu...
Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene...
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )
17 Dec 2019
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell l...
Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )
17 Dec 2019
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory c...
Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )
17 Dec 2019
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?
Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )
17 Dec 2019
Predicting early relapse in transplant-eligible MM patients using baseline progn...
Dr Francesca Gay - University of Torino, Torino, Italy
Predicting early relapse in transplant-eligible MM patients using baseline prognostic features and MRD negativity ( Dr Francesca Gay - University of Torino, Torino, Italy )
17 Dec 2019
Using multiparameter flow cytometry and next generation sequencing to evaluate M...
Dr Francesca Gay - University of Torino, Torino, Italy
Using multiparameter flow cytometry and next generation sequencing to evaluate MRD in NDMM patients from the FORTE trial ( Dr Francesca Gay - University of Torino, Torino, Italy )
17 Dec 2019
Complete remission after induction chemotherapy determines clinical efficacy of ...
Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden
Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML ( Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden )
17 Dec 2019
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patie...
Prof David Cairns - University of Leeds, Leeds, UK
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM ( Prof David Cairns - University of Leeds, Leeds, UK )
17 Dec 2019
Myeloma highlights from ASH 2019
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Myeloma highlights from ASH 2019 ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019
FLT3-inhibition in infants with acute lymphoblastic leukaemia
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
FLT3-inhibition in infants with acute lymphoblastic leukaemia ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )
13 Dec 2019
Chronic lymphocytic leukaemia highlights from ASH 2019
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
Chronic lymphocytic leukaemia highlights from ASH 2019 ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
13 Dec 2019